E-LIB Suche - Ergebnisse für: Benedict, Ágnes

1

Cost–effectiveness analysis for avelumab first-line mainten..:

Critchlow, Simone ; Bullement, Ash ; Crabb, Simon...
Future Oncology. 20 (2024) 8 - p. 459-470 , 2024

Link: https://doi.org/10.2217/..

2

A cost‐effectiveness analysis of avelumab plus best support..:

Su, Po‐Jung ; Xiao, Ying ; Lin, Amy Y....
Cancer Reports. 6 (2023) 10 - p. , 2023

Link: https://doi.org/10.1002/..

3

P857: COMPARISON OF MULTIPLE MYELOMA TREATMENT PATTERNS IN ..:

Rivolo, Simone ; Capart, Philippe ; Benedict, Agnes
HemaSphere. 7 (2023) S3 - p. e397050f , 2023

Link: https://doi.org/10.1097/..

4

A Framework for Integrating Continuous Glucose Monitor-Deri..:

Benedict, Ágnes ; Hankosky, Emily R. ; Marczell, Kinga...
PharmacoEconomics. 40 (2022) 8 - p. 743-750 , 2022

Link: https://doi.org/10.1007/..

5

Prevalence of Immature Survival Data for Anti-Cancer Drugs ..:

Tai, Ting-An ; Latimer, Nicholas R. ; Benedict, Ágnes..
Value in Health. 24 (2021) 4 - p. 505-512 , 2021

Link: https://doi.org/10.1016/..

6

A European survey on the insights of patients living with m..:

Maravic, Zorana ; Rawicka, Iga ; Benedict, Agnes...
ESMO Open. 5 (2020) 5 - p. e000850 , 2020

Link: https://doi.org/10.1136/..

7

Budget Impact Of Including Avelumab As A Second-Line Treatm..:

Kongnakorn, Thitima ; Bharmal, Murtuza ; Kearney, Mairead...
ClinicoEconomics and Outcomes Research. 11 (2019) - p. 659-672 , 2019

Link: https://doi.org/10.2147/..

8

Assessment-Schedule Matching in Unanchored Indirect Treatme..:

Kapetanakis, Venediktos ; Prawitz, Thibaud ; Schlichting, Michael...
PharmacoEconomics. 37 (2019) 12 - p. 1537-1551 , 2019

Link: https://doi.org/10.1007/..

9

Axitinib, cabozantinib, or everolimus in the treatment of p..:

Proskorovsky, Irina ; Benedict, Agnes ; Negrier, Sylvie...
BMC Cancer. 18 (2018) 1 - p. , 2018

Link: https://doi.org/10.1186/..

10

Clinical and Economic Outcomes Associated with Treatment Se..:

Tarhini, Ahmad ; McDermott, David ; Ambavane, Apoorva...
Immunotherapy. 11 (2018) 4 - p. 283-295 , 2018

Link: https://doi.org/10.2217/..

11

Sequential Treatment Approaches inthe Management ofBRAFWild..:

Tarhini, Ahmad ; Benedict, Agnes ; McDermott, David...
Immunotherapy. 10 (2018) 14 - p. 1241-1252 , 2018

Link: https://doi.org/10.2217/..

12

Simulation and Matching-Based Approaches for Indirect Compa..:

Ishak, K. Jack ; Proskorovsky, Irina ; Benedict, Agnes
PharmacoEconomics. 33 (2015) 6 - p. 537-549 , 2015

Link: https://doi.org/10.1007/..

13

Model-Based Cost-Effectiveness Analyses for the Treatment o..:

Marsh, Kevin ; Xu, Peng ; Orfanos, Panagiotis...
PharmacoEconomics. 32 (2014) 9 - p. 853-864 , 2014

Link: https://doi.org/10.1007/..

14

Overview of Parametric Survival Analysis for Health-Economi..:

Ishak, K. Jack ; Kreif, Noemi ; Benedict, Agnes.
PharmacoEconomics. 31 (2013) 8 - p. 663-675 , 2013

Link: https://doi.org/10.1007/..

15

INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST..:

Sorensen, Sonja V. ; Goh, Jo Wern ; Pan, Feng...
International Journal of Technology Assessment in Health Care. 28 (2012) 1 - p. 12-21 , 2012

Link: https://doi.org/10.1017/..